GlassScriptPhysician profile
Zachariah E Tempelmeyer
NPI 1487660601
$1,550.00
in general payments reported to CMS, 2019-2025
27 companies · $182 in 2025
The $182 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $27.84 · 2021: $303 · 2022: $456 · 2023: $180 · 2024: $193 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $522 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $522.28 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $243.23 | 2019-2025 | Evenity, Prolia |
| Bayer Healthcare Pharmaceuticals INC. | $238.27 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $150.29 | 2021-2025 | |
| Novo Nordisk INC | $145.82 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $87.08 | 2021-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $74.18 | 2020-2025 | Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.91 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $67.85 | 2019 | |
| Abbvie INC. | $64.15 | 2021-2025 | Qulipta |
| Pfizer INC. | $59.02 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.68 | 2021-2023 | Jardiance |
| Allergan, INC. | $33.12 | 2019-2020 | |
| Amarin Pharma, INC. | $28.59 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $26.96 | 2021 | |
| Mylan Specialty L.P. | $26.41 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $23.80 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $20.30 | 2021 | |
| Philips North America LLC | $20.01 | 2019 | |
| Exact Sciences Corporation | $15.49 | 2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $15.15 | 2022 | |
| Merck Sharp & Dohme LLC | $14.31 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.11 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $13.69 | 2024 | |
| Sanofi Pasteur INC. | $13.39 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.57 | 2022 | |
| Optinose US, INC. | $12.19 | 2019 | |
| Genentech USA, INC. | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zachariah Tempelmeyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.